Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO Establishes Principles For Follow-on Biologics To Guide Lawmakers

This article was originally published in The Pink Sheet Daily

Executive Summary

In letters sent to legislators, BIO asks Congress to adopt the principles, emphasizing patient health and biotech innovation.

You may also be interested in...



PDUFA Bill Moves To Senate Mark-Up, But Without Generic Biologics Language

April 18 session is planned in the HELP Committee as advocates for follow-on pathway continue to press their case.

PDUFA Bill Moves To Senate Mark-Up, But Without Generic Biologics Language

April 18 session is planned in the HELP Committee as advocates for follow-on pathway continue to press their case.

Exclusivity For Biologics Should Potentially Be Longer Than For Small Molecule Drugs – BIO Exec

In debate over follow-on biologics pathway, BIO and GPhA agree on little except the need to lay out intellectual property ground rules.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel